
Promatix Biosciences has secured funding through Innovate UK’s Biomedical Catalyst programme to support preclinical development of its lead bispecific antibody-drug …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

